As­traZeneca's planned takeover of Alex­ion clears last reg­u­la­to­ry re­view, deal to close next week

4 years ago
Deals

AI start­up En­tos looks to one-up the rest of the field by fold­ing quan­tum me­chan­ics in­to its dis­cov­ery plat­form

4 years ago
Financing
Startups

Eli Lil­ly swoops in to buy a small pro­tein drug de­vel­op­er and its glu­cose re­spon­sive in­sulin in $1B-plus deal

4 years ago
Deals

A cou­ple months af­ter land­ing $100 mil­lion in fund­ing, Cel­lares grabs part­ner for its Cell Shut­tle

4 years ago
Outsourcing
Manufacturing

Nkar­ta signs its name to an am­bi­tious fu­ture with man­u­fac­tur­ing hub for not one but mul­ti­ple mar­ket­ed drugs

4 years ago
Cell/Gene Tx
Manufacturing

Tessera Ther­a­peu­tics taps for­mer BeiGene CFO Howard Liang to join race to CRISPR 3.0

4 years ago
People

Scoop: Ac­tivist­s' at­tempt to take over in­fa­mous Mar­tin Shkre­li com­pa­ny fails, as ‘Phar­ma Bro’ votes from prison

4 years ago
Deals

In re­ver­sal, em­ploy­ers, union groups push for Con­gress to al­low Medicare to ne­go­ti­ate drug prices

4 years ago
Pharma

Astel­las signs on pluripo­tent stem cell part­ners at Ex­CellThera; Lit­tle Uni­cy­cive brings home $25M af­ter float­ing a ...

4 years ago
News Briefing

Covid-19 roundup: Sci­en­tists in­ves­ti­gate po­ten­tial safe­ty changes to J&J and As­traZeneca vac­cines; WTO lists crit­i­cal ...

4 years ago
Coronavirus

Flush with cash, com­pu­ta­tion­al chem­istry pi­o­neer Nim­bus con­sid­ers next steps. Is an IPO in the fu­ture?

4 years ago
Financing

Strug­gling Io­n­is li­cens­es Bi­cy­cle Ther­a­peu­tic­s' plat­form in a bid to de­vel­op drugs that can cross blood-brain bar­ri­er

4 years ago
Deals

Bap­tized by Covid-19 fire, Brii Bio reaps $320M Hong Kong IPO to car­ry on with pipeline for in­fec­tious dis­eases and ...

4 years ago
Financing
China

FDA rais­es safe­ty, ef­fi­ca­cy ques­tions for Fi­bro­Gen's ane­mia drug rox­adu­s­tat with ad­comm on the hori­zon

4 years ago
FDA+

Per­cep­tive hits the pric­ing sweet spot on its lat­est SPAC, kick­start­ing the search for next for­ev­er part­ner

4 years ago
Financing

With Eli Lil­ly's back­ing, a team of Seagen vet­er­ans with ADC chops is look­ing to crash the Chi­nese on­col­o­gy par­ty

4 years ago
Financing
China

Biden ex­ec­u­tive or­der lifts ban on us­ing march-in rights to low­er drug costs

4 years ago
FDA+

House com­mit­tees kick off in­ves­ti­ga­tion in­to how Bio­gen's Aduhelm won ap­proval

4 years ago
Pharma
FDA+

In search of a post-Tec­fidera hit for MS, Bio­gen fol­lows Sanofi, Roche down the BTK path — and bets $125M cash on a ...

4 years ago
Deals
China

CMS kicks off 9-month process on whether to lim­it cov­er­age to Bio­gen's new Alzheimer's drug

4 years ago
Pharma

David Liu takes the wraps off $315M launch round for Prime Med­i­cine and new CRISPR tech that gave Bob Nelsen a 'holy ...

4 years ago
Financing
Startups

Zan­tac man­u­fac­tur­ers off the hook af­ter judge dis­miss­es neg­li­gence and fail­ure-to-warn claims in class-ac­tion law­suit

4 years ago
FDA+

FDA adds sec­ond warn­ing to J&J's Covid-19 vac­cine on da­ta link­ing it to rare nerve con­di­tion

4 years ago
FDA+
Coronavirus

Af­ter month­s­long lull, Big Phar­ma should be ready to pounce on M&A as mar­ket set­tles — an­a­lysts

4 years ago
Deals
First page Previous page 677678679680681682683 Next page Last page
A service from the Financial Times